2024.6-至今 中国科学院生物与化学交叉研究中心，研究员、课题组长
2020.1-2024.5 美国密歇根大学医学院，博士后
2019.7-2020.1 中国科学院上海有机化学研究所，助理研究员
2016.9-2019.6 中国科学院上海有机化学研究所，有机化学博士
2013.9-2016.6 南昌大学/中国科学院上海药物研究所，药物化学硕士
2012.7-2013.8 中国科学院上海药物研究所，本科毕业设计
2009.9-2013.7 南昌大学，药学本科
本课题组主要从事基于靶向蛋白降解技术的小分子药物发现及靶标验证研究，致力于突破靶向蛋白降解研究领域的关键瓶颈，开发新一代靶向蛋白降解类药物，扩大其靶标和适应症范围，同时探索实现细胞外靶标降解的新型策略，并以获得的高活性、高选择性且具良好成药性的靶蛋白降解剂来验证相应靶标在治疗炎症、神经系统疾病等疾病方面的药效和作用机制。此外，本课题组也在积极探索调控蛋白空间互作的新型化学诱导接近技术，以开发出具有全新作用机制且更加高效精准的新一代小分子治疗药物。
（1）靶向转录因子的分子胶降解剂的理性开发及抗神经系统疾病研究
（2）新型E3连接酶的小分子配体开发及其应用
（3）靶向炎症、神经退行性疾病的蛋白降解类药物的发现及成药性优化
（4）靶向细胞外蛋白降解的小分子药物开发
（5）重塑致病蛋白空间互作的双功能小分子抗肿瘤药物的开发
2019年：中国科学院优秀毕业生
2019年：北京市优秀毕业生
1. Zhixiang Chen,# Harshil Dhruv,# Xuqing Zhang,# Rohan Kalyan Rej,# Longchuan Bai,# Donna McEachern, Paul Kirchhoff, Rakesh Nagilla, Larry J. Jolivette, Cory T. Rice, Peter Orth, Corey O. Strickland, E. Scott Priestley, Helai P. Mohammad, Meilin Wang, Bo Wen, Duxin Sun, Zhihua Sui, Shaomeng Wang. Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy. Nature Communications, 2025, 16, 4095.
2. Jie Luo,# Zhixiang Chen,# Yuanyuan Qiao,# Jean Ching-Yi Tien, Eleanor Young, Rahul Mannan, Somnath Mahapatra, Rupam Bhattacharyya, Lanbo Xiao, Tongchen He, Sanjana Eyunni, Yuping Zhang, Yang Zheng, Fengyun Su, Xuhong Cao, Rui Wang, Yunhui Cheng, Rithvik Seri, James George, Miriam Shahine, Stephanie J. Miner, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Ulka Vaishampayan, Mi Wang, Shaomeng Wang, Abhijit Parolia, Arul M. Chinnaiyan. Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer. Nature Genetics, 2025, 57, 2468. (Highlighted as “Research Highlight” by Nature Review Drug Discovery; Highlighted as “Research Briefing” by Nature Genetics)
3. Zhixiang Chen, Yongwen Jiang, Li Zhang, Yinlong Guo, Dawei Ma. Oxalic diamides and tert-butoxides: Two types of ligands enabling practical access to alkyl aryl ethers via Cu-catalyzed coupling reaction. Journal of the American Chemical Society, 2019, 141, 3541. (ESI高被引论文)
4. Zhixiang Chen,# Mi Wang,# Dimin Wu,# Longchuan Bai, Tianfeng Xu, Hoda Metwally, Yu Wang, Donna McEachern, Lijie Zhao, Ruiting Li, John Takyi-Williams, Meilin Wang, Lu Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang. Discovery of CBPD-268 as an exceptionally potent and orally efficacious CBP/p300 PROTAC degrader capable of achieving tumor regression. Journal of Medicinal Chemistry, 2024, 67, 5275. (被评为“Featured Article”)
5. Zhixiang Chen,# Mi Wang,# Dimin Wu, Lijie Zhao, Hoda Metwally, Wei Jiang, Yu Wang, Longchuan Bai, Donna McEachern, Jie Luo, Meilin Wang, Qiuxia Li, Aleksas Matvekas, Bo Wen, Duxin Sun, Arul M Chinnaiyan, Shaomeng Wang. Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP/p300 PROTAC degrader for the treatment of advanced prostate cancer. Journal of Medicinal Chemistry, 2024, 67, 5351.
6. Zhixiang Chen,# Biao Hu,# Rohan Kalyan Rej,# Dimin Wu,# Ranjan Kumar Acharyya,# Mingliang Wang,# Tianfeng Xu,# Jianfeng Lu, Hoda Metwally, Yu Wang, Donna McEachern, Longchuan Bai, Christina L Gersch, Meilin Wang, Wenjing Zhang, Qiuxia Li, Bo Wen, Duxin Sun, James M Rae, Shaomeng Wang. Discovery of ERD-3111 as a potent and orally Efficacious estrogen receptor PROTAC degrader with strong antitumor activity. Journal of Medicinal Chemistry, 2023, 66, 12559.
7. Zhixiang Chen and Dawei Ma. Cu/N,N’-dibenzyloxalamide catalyzed N-arylation of heteroanilines. Organic Letters, 2019, 21, 6874.
8. Rohan Kalyan Rej,# Biao Hu,# Zhixiang Chen,# Ranjan Kumar Acharyya,# Dimin Wu,# Hoda Metwally, Yu Wang, Wei Jiang, Longchuan Bai, Leticia S Nishimura, Christina L. Gersch, Meilin Wang, Bo Wen, Duxin Sun, Kathryn Carlson, John A. Katzenellenbogen, Guozhang Xu, Weihong Zhang, Wenxue Wu, E. Scott Priestley, Zhihua Sui, James M. Rae, Shaomeng Wang. Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα). Journal of Medicinal Chemistry, 2024, 67, 20933.
9. Ranjan Kumar Acharyya,# Rohan Kalyan Rej,# Biao Hu,# Zhixiang Chen,# Dimin Wu,# Jianfeng Lu, Hoda Metwally, Donna McEachern, Yu Wang, Wei Jiang, Longchuan Bai, Jelena Tosovic, Christina L. Gersch, Guozhang Xu, Weihong Zhang, WenXue Wu, E. Scott Priestley, Zhihua Sui, Farzad Sarkari, Bo Wen, Duxin Sun, James M. Rae, Shaomeng Wang. Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer. Journal of Medicinal Chemistry, 2024, 67, 19010.
#共同第一作者
